WideCells Group’s stem cell healthcare insurance CellPlan can now be purchased by Biovault customers – an offering the Group claims to be a first in Britain. Biovault is the UK's largest private human tissue storage facility.
CellPlan – which provides cover for up to €1 million of medical, travel, and accommodation expenses – shoulders the high-cost of stem cell treatment for individuals who have spent on storage of stem cells sourced from umbilical cords. The average price of the insurance product is £170 per annum.
In addition to the coverage, customers will have access to an expert second medical opinion as well as a global concierge service in the event that the treatment is carried out overseas.
WideCells said Biovault is a member of the CellPlan Excel Programme, which means that the storage facility adheres to the Group’s stringent quality standards. Currently it stores more than 25,000 cord blood samples.
João Andrade, WideCells chief executive, said, “With first sales expected imminently, this is a milestone for CellPlan and the Group as a whole. We are leveraging Biovault's register of over 25,000 samples to generate sales of our innovatively complete stem cell insurance product and are delighted that all new customers of the UK’s leading cord blood storage facility will become customers of CellPlan.”
WideCells said CellPlan’s agreement with Biovault can be used as a benchmark for future agreements with other cord blood storage facilities.
Meanwhile, the niche insurance provider also announced that its e-commerce platform will be put live soon.
Related stories:
Stem cell insurance firm makes stock market debut
National Friendly to write health policies again
